Company intelligence / Profile preview

Hepalys Pharma

Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

Hepalys Pharma initiated a Phase 1 trial for lanifibranor in Japan in 2025, representing the first step for local development of this pan-PPAR agonist in MASH (NASH). Lanifibranor previously demonstrated efficacy in global Phase 2b studies, showing reduction in fibrosis and resolution of NASH. A global Phase 3 trial is ongoing, with Hepalys responsible for Asian development, and the company is aiming to accelerate approval in Japan and South Korea.[6][5][2]

Therapeutic areas: OncologyMetabolic DisordersGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Inventiva

Beyond the preview

Go deeper on Hepalys Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepalys Pharma.

Explore the full profile